Previous 10 | Next 10 |
Vistagen (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders. Together with Fuji Pharma Co. (TSE: 4554), a pharmaceutical company ...
2023-09-05 09:29:57 ET More on VistaGen Seeking Alpha’s Quant Rating on VistaGen Therapeutics Historical earnings data for VistaGen Therapeutics Financial information for VistaGen Therapeutics Vistagen Therapeutics, Inc. ( VTGN ) Q1 2024 Earnings...
Vistagen to receive $1.5 million and Fuji to obtain time-limited exclusive negotiation period for the Japanese market Recently reported exploratory Phase 2A study in women diagnosed with menopausal hot flashes demonstrated PH80’s statistically significant reduction in the number of...
Vistagen (NASDAQ: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders. The company today announced its appointment of Cindy Anderson a...
2023-08-22 08:48:52 ET More on VistaGen Therapeutics Vistagen Therapeutics, Inc. ( VTGN ) Q1 2024 Earnings Call Transcript Vistagen up 905% on phase 3 social anxiety drug results Vistagen posts real world data to highlight hot flashes therapy Seeking Alph...
Anderson succeeds Jerrold Dotson who is retiring after a distinguished decade-long career with Vistagen Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other centr...
2023-08-14 08:32:23 ET AMC Entertainment Holdings ( AMC ) -33% . BioXcel Therapeutics BTAI -32% after Q2 earning release . Bridgeline Digital BLIN -19% after Q3 earning release . Black Spade Acquisition Co ( BSAQ ) -16% . Fortrea Holdings FT...
2023-08-13 05:24:05 ET Vistagen Therapeutics, Inc. (VTGN) Q1 2024 Earnings Conference Call August 10, 2023, 04:30 PM ET Company Participants Mark Flather - VP of IR Shawn Singh - CEO Josh Prince - SVP of Business Operations Conference Call Participants ...
Vistagen Therapeutics (NASDAQ: VTGN) , a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, is reporting its financial results for the first qua...
2023-08-11 08:16:36 ET Cano Health ( CANO ) -48% after Q2 earning release . Yield10 Bioscience ( YTEN ) -46% . Maxeon Solar Technologies, Ltd. ( MAXN ) -26% after Q2 earning release . LQR House ( LQR ) -17% . Vistagen Therapeutics ( ...
News, Short Squeeze, Breakout and More Instantly...
VistaGen Therapeutics Inc. Company Name:
VTGN Stock Symbol:
NASDAQ Market:
VistaGen Therapeutics Inc. Website:
Vistagen Therapeutics (NASDAQ: VTGN ), a clinical-stage, neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, has received multiple new patent...
Vistagen (Nasdaq: VTGN), a clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, today announced the broadening of its global in...
Vistagen (NASDAQ: VTGN) , a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that it has been recognized by Mental Health America (“MHA”) for its dedication to pr...